(2012). Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.2308.
(2016). Weight change and healthcare resource use in English patients with type 2 diabetes mellitus initiating a new diabetes medication class. Int J Clin Pract. http://doi.org/10.1111/ijcp.12746.
(2016). Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study. Diabetes Ther. http://doi.org/10.1007/s13300-016-0193-8.
(2017). Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up. Prim Care Diabetes. http://doi.org/10.1016/j.pcd.2017.04.004.
(2019). Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus. Diabetes Res Clin Pract. http://doi.org/10.1016/j.diabres.2019.107791.
(2021). Evaluating a Cox marginal structural model to assess the comparative effectiveness of inhaled corticosteroids versus no inhaled corticosteroid treatment in chronic obstructive pulmonary disease. Ann Epidemiol. http://doi.org/10.1016/j.annepidem.2021.11.004.